nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.08.2009 | Original Paper

Elevated PRL-3 expression was more frequently detected in the large primary gastric cancer and exhibits a poor prognostic impact on the patients

verfasst von: Zhao Wang, Shi-Rong Cai, Yu-Long He, Wen-Hua Zhan, Chang-Hua Zhang, Hui Wu, Jian-Jun Peng, Jian-Bo Xu, Xin-Hua Zhang, Liang Wang, Wu Song

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 8/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

It has been reported that elevated PRL-3 expression was closely associated with lymph node metastasis of gastric cancer. In the present study, we detected the expression of PRL-3 in primary gastric cancer tissue, and evaluated its prognostic impact on the patients.

Methods

Total 137 gastric tumor samples were measured for PRL-3 phosphatase expression using immunohistochemistry method, and the overall survival rate was compared between the patients with high PRL-3 expression (n = 85) and those with moderate or low PRL-3 expression (n = 52) in the primary tumor.

Results

PRL-3 expression was more frequently detected in the tumors with a diameter >40 mm and in advanced stages (TNM stage III or IV). Furthermore, the overall survival rate of the patients with high expression of PRL-3 in the primary tumor was significantly less than those with moderate or low expression (P < 0.001).

Conclusions

PRL-3 expression is associated with gastric cancer progression. Its high expression in the primary lesion had a negative impact on the prognosis of the patients. This strongly suggests that PRL-3 should be considered as a prognostic factor.

Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman A, Godzik A, Hunter T, Dixon J, Mustelin T (2004) Protein tyrosine phosphatases in the human genome. Cell 117:699–711. doi:10.1016/j.cell.2004.05.018 PubMedCrossRef

Guo K, Li J, Tang JP, Koh V, Gan BQ, Zeng Q (2004) Catalytic domain of PRL-3 plays an essential role in tumor metastasis: formation of PRL-3 tumors inside the blood vessels. Cancer Biol Ther 3:945–951PubMed

Hooft van Huijsduijnen R, Bombrun A, Swinnen D (2002) Selecting protein tyrosine phosphatases as drug targets. Drug Discov Today 7:1013–1019. doi:10.1016/S1359-6446(02)02438-8 PubMedCrossRef

Kato H, Semba S, Miskad UA, Seo Y, Kasuga M, Yokozaki H (2004) High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases. Clin Cancer Res 10:7318–7328. doi:10.1158/1078-0432.CCR-04-0485 PubMedCrossRef

Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T (2002) Identification of tissue-specific microRNAs from mouse. Curr Biol 12:735–739. doi:10.1016/S0960-9822(02)00809-6 PubMedCrossRef

Li Z, Zhan W, Wang Z, Zhu B, He Y, Peng J, Cai S, Ma J (2006) Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis. Biochem Biophys Res Commun 348:229–237. doi:10.1016/j.bbrc.2006.07.043 PubMedCrossRef

Matter WF, Estridge T, Zhang C, Belagaje R, Stancato L, Dixon J, Johnson B, Bloem L, Pickard T, Donaghue M, Acton S, Jeyaseelan R, Kadambi V, Vlahos CJ (2001) Role of PRL-3, a human muscle-specific tyrosine phosphatase, in angiotensin-II signaling. Biochem Biophys Res Commun 283:1061–1068. doi:10.1006/bbrc.2001.4881 PubMedCrossRef

Miskad UA, Semba S, Kato H, Yokozaki H (2004) Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis. Pathobiology 71:176–184. doi:10.1159/000078671 PubMedCrossRef

Miskad UA, Semba S, Kato H, Matsukawa Y, Kodama Y, Mizuuchi E, Maeda N, Yanagihara K, Yokozaki H (2007) High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study. Virchows Arch 450:303–310. doi:10.1007/s00428-006-0361-8 PubMedCrossRef

Parker BS, Argani P, Cook BP, Liangfeng H, Chartrand SD, Zhang M, Saha S, Bardelli A, Jiang Y, St Martin TB, Nacht M, Teicher BA, Klinger KW, Sukumar S, Madden SL (2004) Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res 64:7857–7866. doi:10.1158/0008-5472.CAN-04-1976 PubMedCrossRef

Pathak MK, Dhawan D, Lindner DJ, Borden EC, Farver C, Yi T (2002) Pentamidine is an inhibitor or PRL phosphatases with anticancer activity. Mol Cancer Ther 1:1255–1264PubMed

Radke I, Gotte M, Kersting C, Mattsson B, Kiesel L, Wulfing P (2006) Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer. Br J Cancer 95:347–354. doi:10.1038/sj.bjc.6603261 PubMedCrossRef

Sager JA, Benvenuti S, Bardelli A (2004) PRL-3: a phosphatase for metastasis? Cancer Biol Ther 3:952–953PubMedCrossRef

Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St Croix B, Romans KE, Choti MA, Lengauer C, Kinzler KW, Vogelstein B (2001) A phosphatase associated with metastasis of colorectal cancer. Science 294:1343–1346. doi:10.1126/science.1065817 PubMedCrossRef

Stoker AW (2005) Protein tyrosine phosphatases and signalling. J Endocrinol 185:19–33. doi:10.1677/joe.1.06069 PubMedCrossRef

Wu X, Zeng H, Zhang X, Zhao Y, Sha H, Ge X, Zhang M, Gao X, Xu Q (2004) Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells. Am J Pathol 164:2039–2054PubMed

Zeng Q, Hong W, Tan YH (1998) Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1. Biochem Biophys Res Commun 244:421–427. doi:10.1006/bbrc.1998.8291 PubMedCrossRef

Zeng Q, Dong JM, Guo K, Li J, Tan HX, Koh V, Pallen CJ, Manser E, Hong W (2003) PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res 63:2716–2722PubMed

Zhou H, Gallina M, Mao H, Nietlispach D, Betz SF, Fetrow JS, Domaille PJ (2003) 1H, 13C and 15N resonance assignments and secondary structure of the human protein tyrosine phosphatase, PRL-2. J Biomol NMR 27:397–398. doi:10.1023/A:1025875618084 PubMedCrossRef

Titel: Elevated PRL-3 expression was more frequently detected in the large primary gastric cancer and exhibits a poor prognostic impact on the patients
verfasst von: Zhao Wang
Shi-Rong Cai
Yu-Long He
Wen-Hua Zhan
Chang-Hua Zhang
Hui Wu
Jian-Jun Peng
Jian-Bo Xu
Xin-Hua Zhang
Liang Wang
Wu Song
Publikationsdatum: 01.08.2009
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 8/2009
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-008-0541-9

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Elevated PRL-3 expression was more frequently detected in the large primary gastric cancer and exhibits a poor prognostic impact on the patients